Melissa Lee, MD
Internal Medicine · Southampton, PANPI 1639140122
Payments from drug & device makers
Across 136 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$454
- Amgen$211
- Lilly USA, LLC$205
- AstraZeneca$189
- Daiichi Sankyo Inc.$159
- Boehringer Ingelheim$127
- plus $940 from 24 others
What the payments were for
- Food & beverage$2,285100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 34 | $454 |
| Amgen | 11 | $211 |
| Lilly USA, LLC | 12 | $205 |
| AstraZeneca | 12 | $189 |
| Daiichi Sankyo Inc. | 7 | $159 |
| Boehringer Ingelheim | 6 | $127 |
| Abbott | 6 | $115 |
| Astellas Pharma US Inc | 6 | $93 |
| Pfizer | 6 | $84 |
| Exact Sciences | 3 | $84 |
| Merck | 6 | $81 |
| GSK | 5 | $80 |
| AbbVie | 4 | $68 |
| LEO Pharma AS | 1 | $38 |
| Johnson & Johnson | 2 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Biogen | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Novartis | 1 | $19 |
| Intra-sana Laboratories | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Exeltis, USA Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$2,285 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 103 | $105,113 |
| MounjaroTirzepatide | 57 | $65,750 |
| TrulicityDulaglutide | 38 | $55,421 |
| OzempicSemaglutide | 28 | $42,839 |
| EliquisApixaban | 37 | $27,445 |
| JanuviaSitagliptin Phosphate | 19 | $17,749 |
| FarxigaDapagliflozin Propanediol | 18 | $13,042 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $8,732 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $7,295 |
| Atorvastatin Calcium | 345 | $4,929 |
| Rosuvastatin Calcium | 199 | $2,943 |
| Levothyroxine Sodium | 218 | $2,909 |
| Metoprolol Succinate | 150 | $2,541 |
| Losartan Potassium | 163 | $2,366 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 17 | $2,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $205 | $121,17195 claims |
| Boehringer IngelheimJardiance | $127 | $105,113103 claims |
| Novo NordiskOzempic | $454 | $42,83928 claims |
| PfizerEliquis | $84 | $27,44537 claims |
| MerckJanuvia | $81 | $17,74919 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $80 | $16,02730 claims |
| AstraZenecaFarxiga | $189 | $13,04218 claims |
| AbbVieSynthroid | $68 | $2,24545 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Southampton
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.